Biora Therapeutics, Inc. (BIORQ)

Biora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-31.54	-124.12	-38.16	-247.41	-192.53	-148.04
Depreciation & Amortization	0.44	0.56	0.91	1.44	1.44	4.68
Other Amortization	3.69	1.6	1.42	1.57	3.66	1.67
Loss (Gain) From Sale of Assets	0.01	0.02	0.54	0.1	0.07	-
Asset Writedown & Restructuring Costs	-	0.1	0.55	-	-	-
Loss (Gain) From Sale of Investments	3	3	-5.73	-	-	-
Stock-Based Compensation	5.94	16.48	7.8	11.96	8.24	2.38
Other Operating Activities	-39.45	45.25	-28.86	117.87	145.95	40.24
Change in Accounts Receivable	-	-	-	-	-	3.43
Change in Inventory	-	-	-	-	-	-3.86
Change in Accounts Payable	1.93	-1.17	-5.07	-8.69	2.83	4.38
Change in Income Taxes	-0.05	-0	-0.83	0.08	0.64	5.56
Change in Other Net Operating Assets	10.1	9.79	1.25	-17.26	-63.24	-16.56
Operating Cash Flow	-45.92	-48.5	-64.42	-167.49	-165.74	-106.12
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Capital Expenditures	-0.28	-0.1	-0.79	-0.86	-3.87	-3.73
Sale of Property, Plant & Equipment	0.02	0.01	-	-	-	-
Investment in Securities	3	-	-	-	-	20.25
Other Investing Activities	2.54	2.54	-	-0.39	-1.07	-
Investing Cash Flow	5.28	2.44	-0.79	-1.24	-4.94	16.53

Financing Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-Term Debt Issued	-	10	-	-	99.71	-
Long-Term Debt Repaid	-	-	-0.01	-1.64	-0.74	-1.28
Net Debt Issued (Repaid)	20.81	10	-0.01	-1.64	98.97	-1.28
Issuance of Common Stock	11.54	18.14	9.11	92.78	116.44	0.55
Common Dividends Paid	-	-	-	-	-	-4.5
Other Financing Activities	-1.08	2.64	-1.8	73.92	-6.99	-0.18
Financing Cash Flow	31.28	30.78	7.3	165.05	229.72	73.64

Net Cash Flow

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Cash Flow	-9.37	-15.28	-57.91	-3.68	59.03	-15.96

Free Cash Flow

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Free Cash Flow	-46.2	-48.6	-65.21	-168.34	-169.62	-109.85
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-5179.71%	-1215050.00%	-21380.00%	-13499.68%	-104700.62%	-76.29%
Free Cash Flow Per Share	-15.33	-30.81	-85.41	-437.68	-1541.23	-5624.34
Levered Free Cash Flow	-16.08	11.93	-72.54	-52.7	-85.75	-87.65
Unlevered Free Cash Flow	-15.19	16.46	-67.09	-46.37	-83.21	-83.57

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash Interest Paid	1.33	2.28	5.87	7.54	3.93	7.53
Cash Income Tax Paid	0.07	0.02	0.03	0.37	0.06	0.01
Change in Working Capital	11.98	8.62	-4.65	-25.86	-59.78	-7.05

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error